Tag: Alecensa

April 11, 2017 Off

Roche’s Alecensa beats crizotinib in certain lung cancer

By Dino Mustafić

Roche’s randomised phase III ALEX study showed that Alecensa (alectinib) as an initial (first-line) treatment significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared to crizotinib in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).